Skip to main content
Premium Trial:

Request an Annual Quote

DNAPrint Kits Will Incorporate Exiqon Technology

NEW YORK, Aug. 28 - DNAPrint Genomics today said it will incorporate into certain of its pharmacogenomics and forensics tests a modified DNA made by Danish microarray firm Exiqon.

The technology, called Locked Nucleic Acid, is a DNA analog that is said to have favorable binding affinity toward complementary DNA and the ability to discriminate between matching and mismatching target sequences, according to DNAPrint.

 

Sarasota, Fla.-based DNAPrint said it hopes the LNA technology will improve the performance of its kits and services. The company did not say how much it paid for the non-exclusive rights to use the LNA.

 

Exiqon, based in Denmark, is privately held.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.